Medical Science News

RSS

XanGo Juice lowers levels of C-reactive protein in overweight and obese people

A new study published in Nutrition Journal indicates that XanGo- Juice, a market-leading, premium mangosteen beverage, has lowered levels of C-reactive protein (CRP) in overweight and obese people in a randomized, double-blind, placebo-controlled human trial.

4 Nov 2009

Laser-scanning microscope records brain activity in freely moving animals

The majority of our life is spent moving around a static world and we generate our impression of the world using visual and other senses simultaneously. It is the ability to freely explore our environment that is essential for the view we form of our local surroundings.

4 Nov 2009

Propylene glycol in e cigarettes might keep us healthy, says researchers

According to the Centers for Disease Control, during 2000-2004, "An estimated 443,000 persons in the United States died prematurely each year from smoking or exposure to secondhand smoke.

4 Nov 2009

Findings may lead to new drug therapies to reduce breast cancer metastasis

Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer.

4 Nov 2009

Study: Estrogen replacement may help protect brain damage

Eighteen years ago this month the National Institutes of Health (NIH) announced that it would sponsor a landmark study to examine women and cardiovascular disease. Known as the Women's Health Initiative (WHI), the study enrolled more than 161,000 women.

4 Nov 2009

Lovastatin-synthesizing enzyme successfully reconstituted

Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.

4 Nov 2009

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.

4 Nov 2009

Scientists identify potential drug target for curing alcohol drinking behavior

A group of drunken fruit flies have helped researchers from North Carolina State and Boston universities identify entire networks of genes-also present in humans-that play a key role in alcohol drinking behavior.

4 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

Scientists discover two genes that can lead to aggressive leukaemia

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.

3 Nov 2009

Entest BioMedical and Quantum Advisors sign Letter of Intent

Entest BioMedical Inc. (OTCBB: ENTB) announced today that it has signed a Letter of Intent with Quantum Advisors, a San Diego based biotechnology consulting firm, to assist Entest with the development of its Stem Cell Therapeutic Treatment for Chronic Obstructive Pulmonary Disease (COPD).

3 Nov 2009

NIH awards Trevena $7.65M Grand Opportunity grant

Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands announced today that it was awarded a $7.65 million Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). This grant will further fund Trevena’s work to identify and characterize functionally selective biased ligands for a wide range of GPCRs.

3 Nov 2009

Researchers identify part of the brain that responds to both facial and vocal expressions of emotion

Researchers at the University of York have identified a part of the brain that responds to both facial and vocal expressions of emotion.

3 Nov 2009

World-record energies for laser accelerated particles achieved

An international team of physicists at Los Alamos National Laboratory has succeeded in using intense laser light to accelerate protons to energies never before achieved. Using this technique, scientists can now accelerate particles to extremely high velocities that would otherwise only be possible using large accelerator facilities. Physicists around the world are examining laser particle acceleration and laser produced radiation for potential future uses in cancer treatment.

3 Nov 2009

Two cancer-causing genes together can lead to aggressive leukaemia

3 Nov 2009

Roche Applied Science to launch the NimbleGen CGX arrays in Europe and Japan

Roche Applied Science will announce the European and Asia Pacific launch of the NimbleGen CGX arrays for microarray-based cytogenetic analysis at a workshop series in four European cities and seven cities in Asia Pacific. The CGX arrays are designed by Signature Genomic Laboratories (Signature Genomics) and provide high-resolution, genome-wide analysis of chromosomal abnormalities.

3 Nov 2009

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.

3 Nov 2009

Pateamine A found to inhibit yet another anti-cancer mechanism

Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. That's the assessment of Daniel Romo, a Texas A&M chemistry professor, and his colleagues at Johns Hopkins University who are pioneers in research involving this novel marine natural product.

3 Nov 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

GICD, Stanford University collaborate to develop stem cell and regenerative medicine therapies

Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) and Stanford University School of Medicine will collaborate in a new consortium funded by the National Heart, Lung and Blood Institute (NHLBI) to develop stem cell and regenerative medicine therapies. GICD investigators, led by GICD Director Deepak Srivastava, MD, will collaborate with a Stanford team led by Robert Robbins, MD, professor and chair of cardiothoracic surgery, to investigate how to use induced pluripotent stem cells, or iPS cells, to repair damaged heart muscle.

3 Nov 2009